---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000080"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:40:12.244728+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025

## Summary
- FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.
- Previously, FDA had extended PDUFA by 3 months (to Q4 2025) and planned an AdComm.
- Troriluzole is for treatment of adult Spinocerebellar Ataxia (SCA).
- FDA's expected decision remains during Q4 2025.

## SEC filing metadata
- accession: 0001935979-25-000080
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000080/0001935979-25-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000080/bhvn-20250821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000080
- JSON: https://secwatch.observer/filing/0001935979-25-000080.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.